Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

pantarei Aug. 14 at 12:42 PM

$SCYX I have been an investor in this disastrous company for several years now, and by this point, I’ve given up on seeing my money again. However, one question continues to haunt me, and frankly, it is mind-boggling that the Company provides no information whatsoever: why are neither GSK in the US nor Hansoh in China giving any sign of the product Ibrexafungerp in their pipelines on their official websites? GSK no longer even mentions Brexafemme in its recent presentations, and Hansoh hasn't mentioned the product anywhere since April 2025, the date Hengmeida was approved. I have done extensive research, and the two products—aka Ibrexafungerp—are nowhere to be found. Is it possible that Scynexis simply couldn't care less and offers zero updates, given that we should be earning at least a few crumbs too? Aren't there market rules to comply with? Is such a total lack of transparency really permissible? I'm in disbelief...

1 · Reply

XZeroDelta Aug. 14 at 1:42 AM

$SCYX GSK knows that the clock is ticking on the ibrexafungerp patent. They are not going to waste the opportunity of selling ibrexafungerp in the market by writing it off. They are also aware of the un-met need for new innovative antifungal therapies. Which is why there was a recent package insert update posted in the accesspoint page which confirms that there is a team at GSK actively working in bringing ibrexa to the market. I would bet that they will consider buying Scynexis once the phase 2 trial for the IV formulation of SCY 247 has been completed because it would prove to them that the new molecule also works. The added benefit from SCY 247 is that it has higher tissue penetration (can cross into the brain without having to perform a craniotomy on the patient) and also the proceeds of selling SCY 247 in the open market if it is eventually approved by the FDA in the future is that they don't have to be shared with Merck.

0 · Reply

ImadogImaMut Aug. 13 at 3:21 PM

$SCYX GSK can not afford to allow robust data on 247 to drop UNless and of course they own the data themselves 💼

1 · Reply

ImadogImaMut Aug. 13 at 3:16 PM

$SCYX

0 · Reply

anachartanalyst Aug. 13 at 3:02 PM

$SCYX https://anachart.com/wp-content/uploads/2026/08/1786633303_soc-img.jpg

0 · Reply

Windy007 Aug. 13 at 2:59 PM

$SCYX Scynexis price target raised to $33 from $24 at Guggenheim Guggenheim raised the firm's price target on Scynexis to $33 from $24 and keeps a Buy rating on the shares to account for quarterly results and the inclusion of SCY-770 estimates into the firm's model. The firm is incorporating SCY-770 into its model with a 30% probability of success and $1.3B in peak annual U.S. sales.

0 · Reply

pjinvestmentco Aug. 13 at 12:20 PM

$SCYX Maxim update Part 3 Antifungal work is still continuing around SCY-247 with the IV-formulation P1 completing dosing and due to report data this quarter (3Q). With oral data in hand, the IV-formulation is important to bolster partnering and/or divesting discussions as having both options for an antimicrobial (bacterial or fungal) is an attractive value proposition.

0 · Reply

pjinvestmentco Aug. 13 at 12:20 PM

$SCYX Maxim update Part 2 On 8/10, Scynexis reported 2Q results with opex of $8.0M and a non-cash gain on derivative liabilities of $14.1M, for a net gain of $7.4M. The company ended the period with $71.1M in cash on the balance sheet which should provide sufficient runway into 2029. The P1 for its oral direct AMPK activator SCY-770, started in late June and is due to report data by the end of 3Q26. The data should inform the design of a P2 study in autosomal dominant polycystic kidney disease (ADPKD) patients, which is expected to start in 4Q26, representing a key event for Scynexis in its transformation into a rare-disease company.

0 · Reply

pjinvestmentco Aug. 13 at 12:19 PM

$SCYX Maxim update Part 1 SCYNEXIS, Inc. (SCYX – $4.86) Rating Buy Price $4.86 Target Price $32.00 MCap (M) $48.3 2Q Review & Outlook: P1 Data for SCY-770 Due by End of 3Q, Paving the Way to P2 in ADPKD Patients in 4Q26

0 · Reply

DataJim Aug. 12 at 9:23 PM

$SCYX 🦠 SCYX — something genuinely new This one actually has a fresh SEC-related development. Adage Capital and affiliates disclosed a 1,041,824-share SCYNEXIS position, including 498,346 shares from warrants, representing 9.99% ownership based on ~9.93M shares.

0 · Reply

Market Cap	47.86M
Revenue (ttm)	20.60M
Net Income (ttm)	-8.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-41.80%
Debt to Equity Ratio	0.00

Volume	100,794
Avg Vol	151,780
Day's Range	N/A - N/A
Shares Out	9.95M
Stochastic %K	63%
Beta	1.09
Analysts	Strong Sell
Price Target	$33.55